The closing price of Rani Therapeutics Holdings Inc (NASDAQ: RANI) was $3.11 for the day, up 2.64% from the previous closing price of $3.03. In other words, the price has increased by $+0.0800 from its previous closing price. On the day, 128133 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of RANI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.33 and its Current Ratio is at 6.33. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 1.90.
On October 11, 2022, UBS started tracking the stock assigning a Buy rating and target price of $15.
On July 27, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $22.H.C. Wainwright initiated its Buy rating on July 27, 2022, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 06 ’23 when Imran Talat bought 10,000 shares for $2.27 per share. The transaction valued at 22,700 led to the insider holds 484,455 shares of the business.
Imran Talat bought 5,000 shares of RANI for $12,850 on Dec 04 ’23. The Chief Executive Officer now owns 474,455 shares after completing the transaction at $2.57 per share. On Nov 29 ’23, another insider, Imran Talat, who serves as the Chief Executive Officer of the company, bought 20,000 shares for $2.05 each. As a result, the insider paid 41,000 and bolstered with 469,455 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RANI now has a Market Capitalization of 78.90M and an Enterprise Value of 60.46M.
Stock Price History:
The Beta on a monthly basis for RANI is 0.91, which has changed by -40.24% over the last 52 weeks, in comparison to a change of 29.57% over the same period for the S&P500. Over the past 52 weeks, RANI has reached a high of $5.81, while it has fallen to a 52-week low of $1.82. The 50-Day Moving Average of the stock is 3.4866, while the 200-Day Moving Average is calculated to be 3.2714.
Shares Statistics:
RANI traded an average of 79.32K shares per day over the past three months and 68.62k shares per day over the past ten days. A total of 26.04M shares are outstanding, with a floating share count of 11.50M. Insiders hold about 55.82% of the company’s shares, while institutions hold 7.73% stake in the company. Shares short for RANI as of Mar 15, 2024 were 1.86M with a Short Ratio of 23.47, compared to 1.67M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.15% and a Short% of Float of 13.71%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.24, while EPS last year was -$0.33. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.14 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.58 and -$1 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.66, with 3 analysts recommending between -$0.46 and -$0.82.
